Tuesday, April 10, 2001
Mologen: New acquisition and new co-operation
Mologen Holding AG has acquired 51% of bcd biomedical consulting + development GmbH in Berlin. bcd is specialised in providing services and R&D-capacity; for genetic vaccination and somatic gene therapy in animals. bcd and Mologen expect from this deal a powerful combination of the specific know how of both companies.
Mologen regards this investment as another important strategic element for strengthening their application-oriented R&D.; The establishment of the wholly owned Mologen Molecular Medicine S.L. in Spain in 2000 has been the first step in realising this strategy.
A further element is a co-operation with Weston Medical Group plc. Both companies have started to develop new application methods for genetic vaccination of humans by combining the core technologies of both companies. Mologen contributes the MIDGE technology, Weston Medical provides with Intraject one of the leading technologies in needlefree injection.